Xbrane Drops Keytruda Rival As It Pares Down Pipeline And Personnel
Swedish Biosimilars Developer Discloses ‘Unfortunately Necessary Measures’ To Cut Costs
• By David Wallace
Xbrane is aiming to achieve positive cash flow by Q1 2025 • Source: Shutterstock 
